Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis.

Author: Fan Cong KONG ¹ ; Min YU ¹ ; Yu Lan ZHOU ¹ ; Shi Xuan WANG ¹ ; Fei LI ¹
Author Information

1. Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Publication Type:Journal Article
MeSH: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols/adverse effects*; Bendamustine Hydrochloride/therapeutic use*; Humans; Immunoconjugates/adverse effects*; Lymphoma, Large B-Cell, Diffuse/drug therapy*; Rituximab/adverse effects*
From: Chinese Journal of Hematology 2022;43(1):66-69
CountryChina
Language:Chinese